# Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

> **NCT00621023** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 7 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Decitabine, Arsenic Trioxide and Ascorbic Acid

## Key facts

- **NCT ID:** NCT00621023
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2013-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621023, "Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00621023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*